Evidence map›Paper›PMID 39657026›Full record

Trial reportTranslational behavioral medicine2025

Assessing multidimensional fidelity in a pilot optimization trial: A process evaluation of four intervention components supporting medication adherence in women with breast cancer.

Sophie M C Green, Christopher D Graham, Michelle Collinson, Pei Loo Ow, Louise H Hall, David P French, Nikki Rousseau, Hollie Wilkes, Christopher Taylor, Erin Raine and 12 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational behavioral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sophie M C GreenLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.ORCID 0000-0002-2622-5377
Christopher D GrahamDepartment of Psychological Sciences & Health, University of Strathclyde, Glasgow G1 1QE, UK.
Michelle CollinsonLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Pei Loo OwLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Louise H HallLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.
David P FrenchManchester Centre for Health Psychology, University of Manchester, Manchester M13 9PL, UK.
Nikki RousseauLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Hollie WilkesLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Christopher TaylorLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Erin RaineLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.
Rachel EllisonLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Daniel HowdonLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.
Robbie FoyLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.
Rebecca E A WalwynLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Jane ClarkDepartment of Clinical and Health Psychology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
Catherine ParbuttMedicines Management and Pharmacy Services, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
Jo WallerWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Jacqueline BuxtonIndependent, Leeds  LS2 9NL, UK.
Sally J L MooreIndependent, Leeds  LS2 9NL, UK.
Galina VelikovaLeeds Institute of Medical Research at St James's, University of Leeds, St James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0003-1899-5942
Amanda J FarrinLeeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9NL, UK.
Samuel G SmithLeeds Institute of Health Sciences, University of Leeds, Leeds LS2 9NL, UK.

Funding

British Lung Foundation APP11/1Macmillan Cancer Support 6488035National Institute for Health Research NIHR NIHR300588NIHR Applied Research Collaboration NIHR200166NIHR Blood Transfusion Research Unit NIHR203334NIHR Health and Social Care Delivery Research NIHR151848NIHR Health Technology Assessment 15/43/07NIHR Health Technology Assessment NIHR134141NIHR Manchester Biomedical Research Centre NIHR203308NIHR Patient Safety Research Collaboration NIHR204293NIHR Programme Grants for Applied Research RP-PG-0216-20003NIHR Programme Grants for Applied Research RP-PG-1016-20005NIHR Programme Grants for Applied Research RP-PG-1016-20007NIHR Public Health Research NIHR135081NIHR Research for Patient Benefit PB-PG-0816-20015The Breast Cancer Now 2019DecPR1367The Yorkshire Cancer Research L417Yorkshire Cancer Research University Academic L389SS
6 · The paper itself

Abstract

Adherence to adjuvant endocrine therapy in women with breast cancer is low. We conducted a 24-1 fractional factorial pilot optimization trial to test four intervention components supporting medication adherence [text messages, information leaflet, acceptance and commitment therapy (ACT), self-management website], in the preparation phase of the multiphase optimization strategy. Guided by the National Institute of Health Behavior Change Consortium fidelity framework, we investigated fidelity of design, training, delivery, receipt, and enactment of four intervention components. Women prescribed adjuvant endocrine therapy (n = 52) were randomized to one of eight experimental conditions comprised of combinations of the four intervention components (ISRCTN: 10487576). We assessed fidelity using self-report data (4 months post-randomization), trial data, ACT session observations, behavior change technique (BCT) coding, and interviews with participants (n = 20) and therapists (n = 6). Design: Each intervention component targeted unique behavior change techniques with some overlap. Training: All 10 therapists passed the competency assessment. Delivery: All leaflets (27/27) and website (26/26) details were sent, and ACT procedural fidelity was high (85.1%-94.3%). A median of 32.5/41 (range 11-41) text messages were delivered, but a system error prevented some messages being sent to 22 of 28 participants. Receipt: Most participants [63.0% (ACT, leaflet) to 71.4% (text messages)] read all or at least some of the intervention components they were randomized to receive. Enactment was reported most positively for ACT. All intervention components demonstrated adequate fidelity. We have provided an exemplar for assessing fidelity using the National Institute of Health Behavior Change Consortium framework in the preparation phase of multiphase optimization strategy.

Indexed as

Antineoplastic Agents, HormonalBehavior TherapyBreast NeoplasmsMedication AdherenceAdultAgedFemaleHumansMiddle AgedPilot ProjectsSelf-ManagementText MessagingAntineoplastic Agents, Hormonalbreast cancerintervention fidelitymedication adherencemultiphase optimization strategyoptimization trialprocess evaluation

Identifiers

PMID39657026
PMCPMC11756324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.